Malignant Neoplasms
Boehringer Ingelheim Acquires Nerio Therapeutics for $1.3 Billion, Expanding Immuno-Oncology Portfolio
Boehringer Ingelheim, Nerio Therapeutics, Immuno-Oncology, Cancer Treatment, Acquisition, Small Molecule Inhibitors
Ipsen Licenses Novel Antibody-Drug Conjugate from Foreseen Biotechnology for Cancer Treatment
Ipsen, Foreseen Biotechnology, Antibody-Drug Conjugate (ADC), Cancer Treatment, Global Licensing Agreement, FS001
Myricx Bio Secures £90m ($114m) Series A Financing to Advance Novel NMTi ADC Therapeutics
Myricx Bio, Series A Financing, NMTi ADC Therapeutics, Novo Holdings, Lilly, Cancer Treatment
Merck KGaA Discontinues Xevinapant Program for Locally Advanced Head and Neck Cancer
Merck KGaA, Xevinapant, Head and Neck Cancer, Phase III Trial, Discontinuation, Cancer Treatment
FDA Halts BioNTech-MediLink ADC Trial Due to ‘Significant Risk of Illness or Injuries’
FDA, BioNTech, MediLink, ADC, Clinical Trial, Safety Concerns, Cancer Treatment
Day One Biopharma Expands Pipeline with $55 Million Acquisition of MabCare’s Phase 1-Ready ADC
Day One Biopharma, MabCare, Antibody Drug Conjugate (ADC), PTK7, Cancer Treatment, Biotech Acquisition, Pipeline Expansion
Gilead’s Magrolimab Ineffective, Linked to Increased Risk of Death in MDS Patients
Gilead, Magrolimab, MDS, Myelodysplastic Syndrome, Cancer Treatment, Clinical Trials, Safety Concerns
ASCO: AbbVie Revamps ADC Portfolio to Replace Chemotherapy
ASCO, AbbVie, ADCs, Chemotherapy, Rova-T, Teliso-V, Cancer Treatment
Akeso and Summit’s Keytruda-Topping Results in NSCLC Generate Significant Interest at ASCO
Akeso, Summit, Keytruda, NSCLC, ASCO, Merck, Ivonescimab, PD-1, VEGF, Cancer Treatment
Illumina’s Board Approves Spin-Off of Grail, a Cancer Diagnostics Firm
Illumina, Grail, spin-off, cancer diagnostics, DNA sequencing